Breakthrough invasive Candida glabrata in patients on micafungin: A novel FKS gene conversion correlated with sequential elevation of MIC

Journal of Clinical Microbiology

Volumn 52, Issue 7, 2014, Pages 2709-2712

  Saraya, Takeshi ^a   Tanabe, Koichi ^b   Araki, Koji ^a   Yonetani, Shota ^a   Makino, Hiroshi ^a   Watanabe, Takayasu ^a   Tsujimoto, Naoki ^a   Takata, Saori ^a   Kurai, Daisuke ^a   Ishii, Haruyuki ^a   Miyazaki, Yoshitsugu ^b   Takizawa, Hajime ^a   Goto, Hajime ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; GENOMIC DNA; MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; FUNGAL PROTEIN; LIPOPEPTIDE;

AGED; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CASE REPORT; DNA EXTRACTION; DNA SEQUENCE; DRUG EFFECT; FKS1 GENE; FKS2 GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; GENE CONVERSION; GENE DELETION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VERY ELDERLY; CANDIDEMIA; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR GENETICS;

AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BASE SEQUENCE; CANDIDA GLABRATA; CANDIDEMIA; ECHINOCANDINS; FUNGAL PROTEINS; GENE CONVERSION; HUMANS; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; SEQUENCE DELETION;

EID: 84903778046     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03593-13     Document Type: Article

References (13)

1. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. http://dx.doi.org/10.1086/596757.
2. Williams JG, Kubelik AR, Livak KJ, Rafalski JA, Tingey SV. 1990. DNA polymorphisms amplified by arbitrary primers are useful as genetic markers. Nucleic Acids Res. 18:6531-6535. http://dx.doi.org/10.1093/nar/18.22.6531. (Pubitemid 20386578)
3. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. 2011. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J. Clin. Microbiol. 49:396-399. http://dx.doi.org/10.1128/JCM.01398-10.
4. Inui S, Nakamura T, Tanabe K, Ohno H, Koike C, Okuda K, Nakata C, Fujimoto H, Ohkura H, Miyazaki Y, Takahashi H. 2011. A case of micafungin-hyposensitive Candida glabrata due to FKS2 gene mutation. Kansenshogaku Zasshi 85:49-53. (In Japanese.)
5. Niimi K, Woods MA, Maki K, Nakayama H, Hatakenaka K, Chibana H, Ikeda F, Ueno K, Niimi M, Cannon RD, Monk BC. 2012. Reconstitution of high-level micafungin resistance detected in a clinical isolate of Candida glabrata identifies functional homozygosity in glucan synthase gene expression. J. Antimicrob. Chemother. 67:1666-1676. http://dx.doi.org/10.1093/jac/dks112.
6. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, Bretagne S, Dromer F, Lortholary O. 2012. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg. Infect. Dis. 18:86-90. http://dx.doi.org/10.3201/eid1801.110556.
7. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130. http://dx.doi.org/10.1016/j.drup.2007.04.002. (Pubitemid 47031054)
8. Katiyar SK, Alastruey-Izquierdo A, Healey KR, Johnson ME, Perlin DS, Edlind TD. 2012. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob. Agents Chemother. 56:6304-6309. http://dx.doi.org/10.1128/AAC.00813- 12.
9. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, Lockhart SR. 2010. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob. Agents Chemother. 54:5042-5047. http://dx.doi.org/10.1128/AAC.00836-10.
10. Katiyar S, Pfaller M, Edlind T. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894. http://dx.doi.org/10.1128/AAC.00349- 06. (Pubitemid 44198725)
11. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699. http://dx.doi.org/10.1128/AAC.00443-09.
12. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
13. Castanheira M, Woosley LN, Messer SA, Diekema DJ, Jones RN, Pfaller MA. 2014. Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob. Agents Chemother. 58:577-580. http://dx.doi.org/10.1128/AAC.01674-13.